Steroid and Antihistamines Modulate Rantes Release in Cultured Peripheral Blood Mononuclear Cells of Atopic Patients
Open Access
- 1 January 2002
- journal article
- research article
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 15 (1) , 27-34
Abstract
RANTES plays a crucial role in cell recruitment in allergic inflammation. We investigated the pharmacological modulation of RANTES release in cultured peripheral blood mononuclear cells obtained from allergic patients with active asthma. Chemokine production was assessed before and after 15 day treatment with histamine-1 receptor antagonists (Loratadine or Cetirizine) and a steroid (Deflazacort), both in unstimulated and PHA-stimulated cell cultures. Results were compared with those obtained from placebo-treated patients. During the treatment period, patients recorded morning and evening peak expiratory flow (PEF) by mini-Wright. PEF absolute values and diurnal variability significantly improved respect to the pre-treatment in steroid-treated patients, in comparison to the placebo and antihistamine-treated groups (p<0.001 and 0.01, respectively). PEF diurnal variability in the antihistamine-treated group were lower than placebo-treated group without statistical significance (p=0.06). No differences could be found in RANTES levels in supernatants of all cultures between the two antihistamines. RANTES release significantly decreased in supernatants of all cell cultures from steroid (p<0.01) and antihistamine (p=0.03 and 0.04) groups after treatments, compared to the basal values; whereas it increased slightly in controls. Co-variance analysis on RANTES levels, adjusting for pre-treatment values, showed a significant reduction of RANTES release by PHA-stimulated PBMCs from steroid (p=0.003) and anti-histamine (p=0.03) groups, with respect to the placebo group. The same statistical tool applied between the steroid and the antihistamine groups showed, after therapy, the lowest levels of RANTES to be associated with steroid treatment (p=0.005). The study shows that steroid is the most effective drug in modulating RANTES release from PBMCs. However, antihistamines, which are able to reduce cell recruitment due to chemokine release, avoiding important side effects, may be useful in long term therapy in controlling and preventing allergic inflammation.Keywords
This publication has 30 references indexed in Scilit:
- Minimal persistent inflammation may be controlled by cetirizineAnnals of Allergy, Asthma & Immunology, 1999
- Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM‐1 expressionClinical & Experimental Allergy, 1997
- Glucocorticoid‐mediated inhibition of RANTES expression in human T lymphocytesFEBS Letters, 1996
- Intranasal Fluticasone Propionate Inhibits Recovery of Chemokines and Other Cytokines in Nasal Secretions in Allergen-Induced RhinitisAnnals of Allergy, Asthma & Immunology, 1996
- CC chemokines in allergic inflammationImmunology Today, 1994
- Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8.Journal of Experimental Medicine, 1993
- RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.Journal of Experimental Medicine, 1992
- Properties of the Novel Proinflammatory Supergene "Intercrine" Cytokine FamilyAnnual Review of Immunology, 1991
- Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTESNature, 1990
- Adhesion receptors of the immune systemNature, 1990